Furthermore, blocking of LILRB1 combined with rituximab and anti-CD47 enhanced antibody-dependent cellular phagocytosis (ADCP) of chronic lymphocytic leukaemia (CLL) cells (285). Here, LILRB1 is linked to B-cell chronic lymphocytic leukemia.